Arcellx Inc.(NASDAQ:ACLX) 
Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
collaboration revenue from related party | 4,949,000 | 7,554,000 | 8,129,000 | 15,266,000 | 26,030,000 | 27,384,000 | 39,256,000 | |||||||||
operating expenses: | ||||||||||||||||
research and development | 35,088,000 | 37,627,000 | 50,801,000 | 44,649,000 | 39,173,000 | 40,953,000 | 32,318,000 | 28,784,000 | 43,807,000 | 28,327,000 | 32,932,000 | 25,943,000 | 83,473,000 | 23,402,000 | 24,401,000 | |
general and administrative | 31,637,000 | 28,653,000 | 26,226,000 | 23,769,000 | 20,473,000 | 21,424,000 | 22,748,000 | 19,365,000 | 16,012,000 | 15,535,000 | 15,437,000 | 14,061,000 | 10,402,000 | 9,207,000 | 8,034,000 | |
total operating expenses | 66,725,000 | 66,280,000 | 77,027,000 | 68,418,000 | 59,646,000 | 62,377,000 | 55,066,000 | 48,149,000 | 59,819,000 | 43,862,000 | 48,369,000 | 40,004,000 | 93,875,000 | 32,609,000 | 32,435,000 | |
income from operations | -61,776,000 | -58,726,000 | -68,898,000 | -53,152,000 | -33,616,000 | -34,993,000 | -15,810,000 | 14,999,000 | -44,862,000 | -29,560,000 | -30,457,000 | -40,004,000 | -93,875,000 | -32,609,000 | -32,435,000 | |
yoy | 83.77% | 67.82% | 335.79% | -454.37% | -25.07% | 18.38% | -48.09% | -137.49% | -52.21% | -9.35% | -6.10% | |||||
qoq | 5.19% | -14.76% | 29.62% | 58.12% | -3.94% | 121.33% | -205.41% | -133.43% | 51.77% | -2.95% | -23.87% | -57.39% | 187.88% | 0.54% | ||
operating margin % | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | 127.19% | -299.94% | -206.68% | -170.04% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | |
other income: | ||||||||||||||||
interest income | 5,995,000 | 5,984,000 | 6,640,000 | 6,434,750 | 8,086,000 | 8,453,000 | 9,200,000 | 4,312,750 | 6,479,000 | 6,304,000 | 4,468,000 | |||||
interest expense | -12,000 | -7,000 | -114,000 | -321,000 | -588,000 | -977,000 | -959,000 | -880,000 | -1,026,000 | |||||||
total other income | 5,995,000 | 5,984,000 | 6,628,000 | 7,576,000 | 7,972,000 | 8,132,000 | 8,612,000 | 5,467,000 | 5,520,000 | 5,424,000 | 3,442,000 | |||||
income before income taxes | -55,781,000 | -52,742,000 | -62,270,000 | -45,576,000 | -25,644,000 | -26,861,000 | -7,198,000 | 20,466,000 | -39,342,000 | -24,136,000 | -27,015,000 | |||||
income tax expense | -29,000 | 329,000 | ||||||||||||||
net income | -55,781,000 | -52,771,000 | -62,270,000 | -47,081,000 | -25,867,000 | -27,202,000 | -7,198,000 | 19,844,000 | -39,336,000 | -23,854,000 | -27,344,000 | -38,992,000 | -92,874,000 | -32,091,000 | -32,385,000 | |
yoy | 115.65% | 94.00% | 765.10% | -337.26% | -34.24% | 14.04% | -73.68% | -150.89% | -57.65% | -25.67% | -15.57% | |||||
qoq | 5.70% | -15.25% | 32.26% | 82.01% | -4.91% | 277.91% | -136.27% | -150.45% | 64.90% | -12.76% | -29.87% | -58.02% | 189.41% | -0.91% | ||
net income margin % | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | 168.27% | -262.99% | -166.79% | -152.66% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | |
other comprehensive loss: | ||||||||||||||||
unrealized gain on marketable securities | 303,000 | -1,051,000 | 2,691,000 | -280,000 | -1,059,000 | 612,000 | -58,000 | -93,000 | 307,000 | |||||||
comprehensive loss | -55,478,000 | -53,017,000 | -62,469,000 | -48,132,000 | -23,176,000 | -27,482,000 | -8,257,000 | 20,456,000 | -39,394,000 | -23,947,000 | -27,037,000 | -38,814,000 | -93,011,000 | -32,309,000 | -32,409,000 | |
net income per share | -0.99 | -0.94 | -1.13 | -0.87 | -0.48 | -0.51 | -0.14 | 0.42 | -0.81 | -0.5 | -0.58 | -0.76 | -2.12 | -0.88 | -1.56 | |
weighted-average common shares outstanding—basic and diluted | 56,587,167 | 56,221,331 | 55,256,464 | 53,566,153 | 53,821,893 | 53,516,907 | 52,757,973 | 48,061,450 | 48,438,094 | 48,106,528 | 46,769,380 | 36,355,758 | 43,819,365 | 36,609,772 | 20,760,722 | |
unrealized loss on marketable securities | -246,000 | -199,000 | -178,000 | 137,000 | 218,000 | 24,000 | ||||||||||
income tax benefit | -141,000 | -223,000 | -341,000 | -622,000 | 6,000 | |||||||||||
collaboration revenue | 11,792,750 | 14,957,000 | 14,302,000 | 17,912,000 | ||||||||||||
yoy | ||||||||||||||||
qoq | -21.16% | 4.58% | -20.15% | |||||||||||||
income tax provision | -282,000 | |||||||||||||||
revenue | ||||||||||||||||
other income | 392,000 | 1,001,000 | 518,000 | 50,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||
current assets: | ||||||||||||||||
cash and cash equivalents | 79,005,000 | 62,336,000 | 80,861,000 | 105,679,000 | 161,846,000 | 100,025,000 | 154,574,000 | 394,583,000 | 126,119,000 | 303,665,000 | 274,892,000 | 64,179,000 | 56,763,000 | 164,540,000 | 127,160,000 | 30,833,000 |
marketable securities | 382,378,000 | 390,767,000 | 462,404,000 | 481,696,000 | 412,408,000 | 416,663,000 | 419,345,000 | 307,434,000 | 313,597,000 | 202,819,000 | 258,701,000 | 190,656,000 | 224,018,000 | 142,446,000 | 83,769,000 | 73,784,000 |
restricted cash, current | 208,000 | 208,000 | 208,000 | 208,000 | 208,000 | 1,903,000 | ||||||||||
prepaid expenses and other current assets | 10,698,000 | 10,792,000 | 10,681,000 | 11,727,000 | 12,839,000 | 13,307,000 | 14,606,000 | 12,443,000 | 20,260,000 | 22,155,000 | 16,544,000 | 12,028,000 | 9,524,000 | 18,761,000 | 9,974,000 | 8,192,000 |
total current assets | 472,081,000 | 463,895,000 | 554,154,000 | 599,310,000 | 587,301,000 | 530,203,000 | 588,733,000 | 716,363,000 | 491,456,000 | 558,070,000 | 571,367,000 | 266,863,000 | 290,305,000 | 325,747,000 | 220,903,000 | 112,809,000 |
restricted cash, non-current | 2,616,000 | 2,418,000 | 2,418,000 | 2,418,000 | 2,418,000 | 2,418,000 | 2,418,000 | 2,418,000 | ||||||||
marketable securities, non-current | 114,591,000 | 84,502,000 | 21,942,000 | 38,277,000 | 102,428,000 | 130,128,000 | 117,102,000 | 27,168,000 | ||||||||
property and equipment | 43,076,000 | 44,472,000 | 45,568,000 | 46,456,000 | 47,497,000 | 46,276,000 | 44,930,000 | 42,728,000 | 37,782,000 | 22,285,000 | 14,421,000 | 11,231,000 | 10,034,000 | 9,660,000 | 10,127,000 | 10,318,000 |
operating lease right-of-use assets | 23,225,000 | 23,416,000 | 23,603,000 | 23,789,000 | 23,934,000 | 24,065,000 | 24,196,000 | 27,099,000 | 29,142,000 | 29,386,000 | 29,645,000 | 28,659,000 | 28,969,000 | 27,449,000 | 3,248,000 | |
prepaid research and development expenses and other long-term assets | 329,000 | 383,000 | 397,000 | 1,077,000 | 1,331,000 | 1,216,000 | 2,316,000 | 9,356,000 | 7,949,000 | 11,286,000 | 5,009,000 | 4,563,000 | 5,518,000 | 9,969,000 | 8,913,000 | |
total assets | 655,918,000 | 619,086,000 | 648,082,000 | 711,327,000 | 764,909,000 | 734,306,000 | 779,695,000 | 825,132,000 | 614,218,000 | 623,528,000 | 622,943,000 | 313,817,000 | 337,327,000 | 375,326,000 | 243,390,000 | 128,782,000 |
liabilities and stockholders’ equity | ||||||||||||||||
current liabilities: | ||||||||||||||||
accounts payable | 4,204,000 | 2,079,000 | 4,369,000 | 2,095,000 | 5,989,000 | 4,868,000 | 3,099,000 | 2,619,000 | 7,185,000 | 5,693,000 | 4,532,000 | 9,053,000 | 2,962,000 | 7,556,000 | 1,874,000 | 1,333,000 |
accrued liabilities | 46,967,000 | 53,034,000 | 43,359,000 | 56,716,000 | 43,038,000 | 42,033,000 | 33,933,000 | 18,302,000 | 16,916,000 | 12,390,000 | 13,997,000 | 11,679,000 | 11,212,000 | 22,059,000 | 14,400,000 | 13,180,000 |
operating lease liabilities, current portion | 7,471,000 | 7,416,000 | 7,361,000 | 7,308,000 | 7,253,000 | 7,199,000 | 7,146,000 | 7,501,000 | 6,582,000 | 6,111,000 | 4,947,000 | 2,901,000 | 2,874,000 | 2,313,000 | 370,000 | |
finance lease liabilities, current portion | 230,000 | 10,865,000 | 19,220,000 | 32,531,000 | 39,283,000 | 48,286,000 | 38,045,000 | 35,294,000 | 33,060,000 | 27,729,000 | ||||||
contract liability to related party | 59,750,000 | 59,321,000 | 57,372,000 | 59,056,000 | 69,872,000 | 14,970,000 | 31,192,000 | 50,533,000 | ||||||||
total current liabilities | 118,392,000 | 121,850,000 | 112,461,000 | 125,405,000 | 137,017,000 | 88,290,000 | 107,901,000 | 118,238,000 | 173,149,000 | 156,114,000 | 166,057,000 | 56,693,000 | 44,777,000 | 32,053,000 | 16,808,000 | 14,845,000 |
operating lease liabilities, net of current portion | 44,323,000 | 45,097,000 | 45,831,000 | 46,542,000 | 47,214,000 | 47,872,000 | 47,685,000 | 50,841,000 | 48,096,000 | 40,638,000 | 31,994,000 | 31,299,000 | 29,212,000 | 27,200,000 | 4,844,000 | |
contract liability to related party, net of current portion | 52,426,000 | 59,916,000 | 69,447,000 | 82,612,000 | 96,081,000 | |||||||||||
other non-current liabilities | 3,437,000 | 8,593,000 | 15,048,000 | 14,899,000 | 15,468,000 | |||||||||||
total liabilities | 215,141,000 | 226,863,000 | 231,176,000 | 256,535,000 | 281,891,000 | 247,142,000 | 283,122,000 | 339,752,000 | 348,090,000 | 329,861,000 | 319,226,000 | 108,863,000 | 101,043,000 | 59,370,000 | 21,799,000 | 16,918,000 |
commitments and contingencies | ||||||||||||||||
stockholders’ equity | ||||||||||||||||
common stock | 56,000 | 54,000 | 54,000 | 53,000 | 53,000 | 53,000 | 53,000 | 52,000 | 48,000 | 48,000 | 48,000 | 44,000 | 44,000 | 44,000 | 36,000 | 1,000 |
additional paid-in capital | 1,107,665,000 | 1,003,635,000 | 975,301,000 | 950,719,000 | 930,813,000 | 911,783,000 | 893,710,000 | 874,261,000 | 675,469,000 | 663,614,000 | 649,717,000 | 523,921,000 | 516,437,000 | 510,761,000 | 384,095,000 | 8,615,000 |
accumulated other comprehensive income | 706,000 | 403,000 | 649,000 | 848,000 | 1,899,000 | -792,000 | -512,000 | 547,000 | 86,000 | |||||||
accumulated deficit | -667,650,000 | -611,869,000 | -559,098,000 | -496,828,000 | -449,747,000 | -423,880,000 | -396,678,000 | -389,480,000 | -409,324,000 | -369,988,000 | -346,134,000 | -318,790,000 | -279,798,000 | -194,587,000 | -162,496,000 | -130,111,000 |
total stockholders’ equity | 440,777,000 | 392,223,000 | 416,906,000 | 454,792,000 | 483,018,000 | 487,164,000 | 496,573,000 | 485,380,000 | 266,128,000 | 293,667,000 | 303,717,000 | 204,954,000 | 236,284,000 | 315,956,000 | 221,591,000 | |
total liabilities and stockholders’ equity | 655,918,000 | 619,086,000 | 648,082,000 | 711,327,000 | 764,909,000 | 734,306,000 | 779,695,000 | 825,132,000 | 614,218,000 | 623,528,000 | 622,943,000 | |||||
contract liabilities, net of current portion to related party | 75,995,000 | 170,673,000 | ||||||||||||||
stockholders’ equity: | ||||||||||||||||
contract liability, net of current portion to related party | 112,068,000 | |||||||||||||||
finance lease liabilities, net of current portion | 5,755,000 | 8,841,000 | 15,413,000 | 20,871,000 | 27,054,000 | |||||||||||
receivable from collaboration partner | 31,480,000 | 29,431,000 | 21,230,000 | |||||||||||||
restricted cash | 4,929,000 | 2,501,000 | 2,501,000 | 2,501,000 | 2,501,000 | 2,501,000 | 199,000 | 199,000 | ||||||||
marketable securities non current | 42,960,000 | |||||||||||||||
contract liability | 94,180,000 | 93,875,000 | 107,287,000 | |||||||||||||
contract liability, net of current portion | 121,090,000 | 124,268,000 | 105,762,000 | |||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of september 30, 2023 or december 31, 2022 | ||||||||||||||||
accumulated other comprehensive loss | -65,000 | -7,000 | -221,000 | -399,000 | -262,000 | -44,000 | -20,000 | |||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of june 30, 2023 or december 31, 2022 | ||||||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of march 31, 2023 or december 31, 2022 | ||||||||||||||||
deferred offering costs | 3,172,000 | |||||||||||||||
liabilities, redeemable convertible preferred stock, and stockholders’ equity | ||||||||||||||||
deferred rent, current portion | 183,000 | |||||||||||||||
other current liabilities | 125,000 | 164,000 | 149,000 | |||||||||||||
deferred rent, net of current portion | 1,895,000 | |||||||||||||||
other long-term liabilities | 117,000 | 147,000 | 178,000 | |||||||||||||
redeemable convertible preferred stock | ||||||||||||||||
series a redeemable convertible preferred stock, par value 0.001 per share... | ||||||||||||||||
series b redeemable convertible preferred stock, par value 0.001 per share... | 85,367,000 | |||||||||||||||
series c redeemable convertible preferred stock, par value 0.001 per share... | 119,118,000 | |||||||||||||||
total redeemable convertible preferred stock | 233,379,000 | |||||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of december 31, 2022; no shares authorized, issued or outstanding as of december 31, 2021 | ||||||||||||||||
total liabilities, redeemable convertible preferred stock, and stockholders’ equity | 313,817,000 | 337,327,000 | 375,326,000 | 243,390,000 | ||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of september 30, 2022; no shares authorized, issued or outstanding as of december 31, 2021 | ||||||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of june 30, 2022; no shares authorized, issued or outstanding as of december 31, 2021 | ||||||||||||||||
preferred stock, par value of 0.001 per share; 200,000,000 shares authorized and no shares issued and outstanding as of march 31, 2022; no shares authorized, issued or outstanding as of december 31, 2021 | ||||||||||||||||
other long-term assets | 2,284,000 | |||||||||||||||
liabilities, redeemable convertible preferred stock, and stockholders’ deficit | ||||||||||||||||
series a redeemable convertible preferred stock, par value of 0.001 per share; 29,795,227 shares authorized at december 31, 2021 and 2020; 5,413,272 shares issued and outstanding at december 31, 2021 and 2020; liquidation value 29,795 at december 31, 2021 and 2020. | 28,894,000 | |||||||||||||||
stockholders’ deficit: | ||||||||||||||||
total stockholders’ deficit | -121,515,000 | |||||||||||||||
total liabilities, redeemable convertible preferred stock, and stockholders’ deficit | 128,782,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||||||||||
net loss | -55,781,000 | -52,771,000 | -62,270,000 | -25,867,000 | -27,202,000 | -7,198,000 | 19,844,000 | -39,336,000 | -23,854,000 | -27,344,000 | -38,992,000 | -85,211,000 | -32,091,000 | -32,385,000 | |
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||
depreciation and amortization | 1,843,000 | 1,618,000 | 1,576,000 | 1,789,000 | 1,334,000 | 1,239,000 | 826,000 | 722,000 | 447,000 | 439,000 | 432,000 | 417,000 | 339,000 | 149,000 | 416,000 |
loss on disposal of property and equipment | 2,000 | ||||||||||||||
non-cash operating lease expense | 190,000 | 188,000 | 186,000 | 131,000 | 131,000 | 2,903,000 | |||||||||
right-of-use asset expensed | -94,000 | 0 | 50,000 | 838,000 | 624,000 | 1,705,000 | |||||||||
amortization of premiums and discounts on marketable securities | -1,666,000 | -2,397,000 | -3,136,000 | -3,568,000 | -3,404,000 | -4,127,000 | -4,360,000 | -3,944,000 | -2,415,000 | -2,711,000 | -1,978,000 | -1,357,000 | -806,000 | -72,000 | 110,000 |
share-based compensation | 17,927,000 | 18,076,000 | 23,817,000 | 15,769,000 | 15,333,000 | 15,139,000 | 14,845,000 | 10,615,000 | 10,614,000 | 10,404,000 | 10,156,000 | 5,790,000 | 5,329,000 | 5,944,000 | 4,481,000 |
changes in operating assets and liabilities: | |||||||||||||||
prepaid expenses and other current and non-current assets | 153,000 | -98,000 | 1,719,000 | 982,000 | 353,000 | 562,000 | 6,714,000 | 6,632,000 | 1,826,000 | -11,886,000 | -4,931,000 | -1,545,000 | 13,683,000 | -9,410,000 | -8,423,000 |
accounts payable and other current liabilities | 1,753,000 | -2,288,000 | 2,241,000 | -3,584,000 | 908,000 | 2,299,000 | 307,000 | -4,826,000 | 2,149,000 | 440,000 | -4,237,000 | 5,925,000 | -4,173,000 | 4,971,000 | 696,000 |
accrued liabilities | -5,924,000 | 9,639,000 | -13,231,000 | 14,376,000 | 954,000 | 9,004,000 | 17,675,000 | 7,013,000 | 176,000 | -1,423,000 | -173,000 | 282,000 | -10,740,000 | 7,500,000 | 2,563,000 |
operating lease liabilities | -719,000 | -678,000 | -659,000 | -617,000 | -604,000 | -567,000 | -1,979,000 | -422,000 | 3,602,000 | 9,268,000 | 1,013,000 | 2,113,000 | 865,000 | 249,000 | -104,000 |
contract liability to related party | -7,060,000 | -7,583,000 | -8,232,000 | -17,432,000 | 41,432,000 | -32,208,000 | -77,946,000 | ||||||||
other non-current liabilities | 0 | -3,437,000 | -5,156,000 | -6,455,000 | 149,000 | -569,000 | 15,468,000 | ||||||||
net cash from operating activities | -49,207,000 | -39,731,000 | -63,145,000 | -46,030,000 | 30,719,000 | -36,249,000 | -31,907,000 | 58,248,000 | -10,102,000 | -22,615,000 | 182,042,000 | -27,520,000 | -16,649,000 | -22,548,000 | -32,586,000 |
capital expenditures | -59,000 | -452,000 | -553,000 | -2,508,000 | -2,026,000 | -4,652,000 | -3,923,000 | -10,658,000 | -4,044,000 | -6,614,000 | 1,729,000 | -936,000 | 10,000 | -149,000 | -432,000 |
free cash flows | -49,266,000 | -40,183,000 | -63,698,000 | -48,538,000 | 28,693,000 | -40,901,000 | -35,830,000 | 47,590,000 | -14,146,000 | -29,229,000 | 183,771,000 | -28,456,000 | -16,639,000 | -22,697,000 | -33,018,000 |
cash flows from investing activities | |||||||||||||||
purchases of property and equipment | -296,000 | -487,000 | -780,000 | -1,499,000 | -2,290,000 | -3,213,000 | -6,432,000 | -5,293,000 | -7,927,000 | -7,228,000 | -980,000 | -1,276,000 | -385,000 | -149,000 | -467,000 |
purchases of marketable securities | -122,130,000 | -156,572,000 | -78,636,000 | -136,321,000 | -59,950,000 | -82,660,000 | -318,380,000 | -42,385,000 | -237,900,000 | 0 | -162,144,000 | -25,757,000 | -128,606,000 | -92,348,000 | -27,026,000 |
proceeds from maturities of marketable securities | 102,400,000 | 167,800,000 | 117,200,000 | 133,700,000 | 98,000,000 | 78,000,000 | 118,000,000 | 68,695,000 | 85,800,000 | 58,500,000 | 96,350,000 | 60,655,000 | 47,571,000 | 33,264,000 | 16,850,000 |
net cash from investing activities | -20,026,000 | 10,741,000 | 37,784,000 | -4,120,000 | 35,760,000 | -7,873,000 | -206,812,000 | 21,017,000 | -160,027,000 | 51,272,000 | -66,774,000 | 33,622,000 | -81,420,000 | -59,233,000 | -10,643,000 |
cash flows from financing activities | |||||||||||||||
proceeds from issuance of common stock in offerings, net of issuance costs | |||||||||||||||
proceeds from exercise of stock options | 772,000 | 1,675,000 | 772,000 | 3,697,000 | 2,289,000 | 4,604,000 | 1,242,000 | 2,966,000 | 374,000 | 344,000 | |||||
proceeds from stock issued pursuant to employee stock purchase plan | 0 | 0 | |||||||||||||
principal payments under finance leases | 0 | -1,000 | -229,000 | -8,355,000 | -13,362,000 | -7,589,000 | |||||||||
tax withholding payments related to net share settlement of restricted stock units | |||||||||||||||
net cash from financing activities | 86,100,000 | 10,257,000 | 543,000 | -6,017,000 | -4,658,000 | -10,427,000 | -2,985,000 | 188,591,000 | -4,989,000 | 116,000 | 95,445,000 | 1,314,000 | -9,708,000 | 121,463,000 | 139,556,000 |
net decrease in cash and cash equivalents and restricted cash | 16,867,000 | -18,733,000 | -24,818,000 | ||||||||||||
cash and cash equivalents and restricted cash, beginning of the period | 0 | 0 | 108,305,000 | 0 | 0 | 398,904,000 | |||||||||
cash and cash equivalents and restricted cash, end of the period | 16,867,000 | -18,733,000 | 83,487,000 | -56,167,000 | 61,821,000 | -54,549,000 | 157,200,000 | 267,856,000 | -175,118,000 | 28,773,000 | 277,393,000 | 7,416,000 | -107,777,000 | 39,682,000 | 127,359,000 |
supplemental disclosure of cash flow information: | |||||||||||||||
cash paid for income taxes | 0 | 168,000 | 401,000 | 0 | 0 | ||||||||||
supplemental disclosures of noncash investing and financing activities: | |||||||||||||||
purchase of property and equipment included in accounts payable and accrued liabilities | 237,000 | 35,000 | 227,000 | -1,009,000 | 264,000 | -1,439,000 | 2,509,000 | -5,365,000 | 3,883,000 | 614,000 | 2,709,000 | 340,000 | 395,000 | 0 | 35,000 |
proceeds from issuance of common stock in offerings, net of transactions costs | |||||||||||||||
net income | |||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||
noncash operating lease expense | 197,000 | 310,000 | 310,000 | 321,000 | 212,000 | 60,000 | |||||||||
proceeds from issuance of common stock (initial public offering), net of transactions costs | 0 | 0 | 0 | 129,156,000 | |||||||||||
proceeds from issuance of common stock in private placement, net of transactions costs | |||||||||||||||
proceeds from issuance of common stock (follow-on offering), net of transactions costs | 0 | -816,000 | |||||||||||||
proceeds from exercise of stock options and early exercise of restricted stock | |||||||||||||||
proceeds from issuance of common stock under the employee stock purchase plan | |||||||||||||||
payments under finance leases | -15,382,000 | -5,703,000 | -3,378,000 | -4,929,000 | -30,000 | -29,000 | |||||||||
net increase in cash and cash equivalents and restricted cash | -56,167,000 | 61,821,000 | -54,549,000 | -241,704,000 | 267,856,000 | -175,118,000 | 28,773,000 | 210,713,000 | 7,416,000 | -107,777,000 | 39,682,000 | 96,327,000 | |||
cash and cash equivalents and restricted cash, beginning of the year | 0 | 0 | 0 | 66,680,000 | 0 | 0 | 0 | 31,032,000 | |||||||
supplemental disclosures of cash flow information: | |||||||||||||||
receivable from collaboration partner | -2,049,000 | -8,201,000 | -21,230,000 | ||||||||||||
proceeds from issuance of common stock in accordance with gilead stock purchase agreement | 0 | 0 | 100,000,000 | ||||||||||||
proceeds from issuance of series c redeemable convertible preferred stock, net of transaction costs | |||||||||||||||
payments for repurchase of restricted stock | |||||||||||||||
payments under capital leases | |||||||||||||||
payments of deferred offering costs | |||||||||||||||
deferred offering costs included in accounts payable and accrued liabilities | |||||||||||||||
contract liability | -2,345,000 | 5,093,000 | 228,319,000 | ||||||||||||
proceeds from issuance of common stock (private placement), net of transactions costs | 0 | 0 | -42,000 | 10,000,000 | |||||||||||
amortization of operating lease right-of-use assets | |||||||||||||||
finance lease right-of-use asset expensed | |||||||||||||||
deferred rent | |||||||||||||||
interest expense | |||||||||||||||
right of use asset expensed | |||||||||||||||
payments under finance lease | |||||||||||||||
proceeds from the exercise of stock options | 429,000 | ||||||||||||||
deferred offering costs included in accrued liabilities | 42,000 | ||||||||||||||
payment for repurchase of restricted stock | |||||||||||||||
proceeds from issuance of series b redeemable convertible preferred stock, net of transaction costs | |||||||||||||||
net increase in cash, cash equivalents and restricted cash | |||||||||||||||
cash, cash equivalents and restricted cash, beginning of the year | |||||||||||||||
cash, cash equivalents and restricted cash, end of the period |